Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial

PD Miller, G Hattersley, BJ Riis, GC Williams, E Lau… - Jama, 2016 - jamanetwork.com
Importance Additional therapies are needed for prevention of osteoporotic fractures.
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. Objective
To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of
new vertebral fracture in postmenopausal women at risk of osteoporotic fracture. Design,
Setting, and Participants The Abaloparatide Comparator Trial In Vertebral Endpoints
(ACTIVE) was a phase 3, double-blind, RCT (March 2011-October 2014) at 28 sites in 10 …